For example, the immunotherapeutic drug pembrolizumab was used in combination with lenvatinib, a targeted drug that inhibits the activity of VEGFR, FGFR, PDGFRα, KIT and Ret, demonstrated promising anti-tumor effect in patients with renal cell carcinoma or endometrial cancer40. Here, RET is linked to renal cell carcinoma.